|
Session 38
Oral Abstracts
Primary HIV Infection, Early Treatment, and Immune-Based Therapies for Chronic Infection
Wednesday, 10 am - 12:30 pm
Room: Room 408 |
| 10:00 am 120LB |
HIV in Genital Fluids During Heterosexual Transmission
Debrah Boeras*1, P Hawkins1, J Mulenga2, S Allen1, and E Hunter1
1Emory Univ, Atlanta, GA, US and 2Zambia Blood Transfusion Svc, Lusaka |
| 10:15 am 121 |
Complex HIV-1 Populations Prior to Seroconversion in Men Who Have Sex with Men: Analysis of HIV-1 Plasma RNA Positive-Seronegative Subjects from the MACS
Geoffrey Gottlieb*1, L Heath1, D Nickle1, K Wong1, A van ’t Wout1, L Jacobson2, J Margolick2, and J Mullins1
1Univ of Washington, Seattle, US and 2Johns Hopkins Univ, Baltimore, MD, US |
| 10:30 am 122 |
HIV-1 Envelopes from Acute and Chronic Infection Differ in their Levels of Fusogenicity and Sensitivity to Inhibition with sCD4
Yang Liu*1, T Wrin1, N Parkin1, C Petropoulos1, S Frost2, S Little2, D Richman2, and W Huang1
1Monogram Biosci, South San Francisco, CA, US and 2Univ of California, San Diego, US |
| 10:45 am 123 |
Immunodomination by HLA-B27- and HLA-B57-restricted HIV-1-specific T-cell Responses Results in Abrogation of other HLA-restricted Responses in Primary HIV-1 Infection
Hendrik Streeck*1, G Alter1, N Teigen1, M Swartz1, R P Sekaly2, A Kelleher3, S Little4, T Allen1, B Walker1, and M Altfeld1
1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch, Boston, US; 2Ctr Hosp Univ Montreal, Canada; 3Ctr for Immunology, St Vincent's Hosp, Darlinghurst, Australia; and 4Antiviral Res Ctr, Univ of California, San Diego, US |
| 11:00 am 124LB |
Early Treatment of Primary HIV-1 Infection Lowers the Viral Set Point
Radjin Steingrover*1,2,3, Radjin Steingrover*1,2,3, Radjin Steingrover*1,2,3, D Bezemer4,5, D Bezemer4,5, E Fernandez Garcia3, F Kroon6, F de Wolf4, M Prins5, J Lange1,2,3, J Lange1,2,3, J Lange1,2,3, and J Prins1
1Academic Med Ctr, Univ of Amsterdam, The Netherlands; 2Natl Antiretroviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 3Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 4HIV Monitoring Fndn, Amsterdam, The Netherlands; 5Municipal Hlth Svc, Amsterdam, The Netherlands; and 6Leiden Univ Med Ctr, The Netherlands |
| 11:15 am 125LB |
No Benefit from Early Treatment in Primary HIV-Infection?
Christine Koegl*1, E Wolf1, H Jessen2, K Schewe3, M Rausch4, J Goelz5, A Goetzenich6, H Knechten6, H Jaeger7, and the Prime-DAG and Ac-DAG Study Group
1MUC Res, Munich, Germany; 2Private Practice, Berlin, Germany; 3Practice St Georg, Hamburg, Germany; 4Priviate Practice, Berlin, Germany; 5HIV Outpatient Practice Kaiserdamm, Berlin, Germany; 6DAGNAE eV, Aachen, Germany; and 7HIV Res and Clin Care Ctr Munich, Germany |
| 11:30 am 126LB |
Time to ART Resumption following Treatment Interruption Is Shorter for Individuals Immunized with HIV-Recombinant Canarypox Vaccine (Vcp1452) Compared to Placebo: The Manon-02 Trial
Brigitte Autran*1, D Costagliola2, R Murphy3, N Wincker4, B Clotet5, J Gatell6, R Tubiana7, S Staszewski8, B Walker9, C Katlama7, and ORVACS Study Group
1Hosp Pitie Salpetriere, INSERM U543, ORVACS, Univ Pierre et Marie Curie, Paris VI, France; 2INSERM U720, Univ Pierre et Marie Curie Paris VI, France; 3Northwestern University Medical School, Chicago, USA; 4ORVACS, Hôpital Pitié Salpêtrière, Paris, France; 5Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Badalona, Spain; 6Hosp y Clin Provincial, Barcelona, Spain; 7Hosp Pitie Salpetriere, ORVACS, INSERM U720, Univ Pierre et Marie Curie, Paris VI, France; 8Klinikum der Johann Wolfgang Goethe Univ, Frankfurt, Germany; and 9Harvard Med Sch, Charlestown, MA, US |
| 11:45 am 127 |
Repeated r-hIL-7 Doses Improve T-cell Recovery in HIV-1-infected Patients Enrolled in a Phase I/II Multicentric Study
Y Levy1,2, Y Levy1,2, L Weiss1,3,4, L Weiss1,3,4, L Weiss1,3,4, J P Viard5, J Molina6, C Goujard7, F Boué8, S Delluc1, C Rouzioux5, M Morre9, and jean-François Delfraissy*7
1INSERM, Creteil, France; 2Henri Mondor Hosp, Creteil, France; 3Hosp Georges Pompidou, Paris, France; Rene-Descartes Univ and INSERM, Creteil, France; 4Rene-Descartes Univ, Paris, France; 5Necker Hosp, Paris, France; 6Hosp St Louis, Paris, France; 7Kremlin-Bicetre Hosp, France; 8Hosp Antoine Beclere, Clamart, France; and 9Cytheris, Issy, France |
| 12:00 pm 128 |
rhIL7 in HIV-1-infected Subjects with CD4 T-cell Count >100cells/µL and Viral Load <50,000 copies/mL: Results from a Randomized, Placebo-controlled, Double-blinded Study (ACTG5214)
Irini Sereti*1, E Aga2, J Spritzler2, A Landay3, S Pahwa4, M Fischl4, D Asmuth5, A Tenorio6, R Buffet7, M Lederman8, and ACTG 5214 team
1NIAID, NIH, Bethesda, MD, US; 2Statistical & Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Rush-Presbyterian Med Coll, Chicago, IL, US; 4Univ of Miami, Miller Sch of Med, FL, US; 5Univ of California, Davis Med Ctr, US; 6Rush-Presbyterian-St Luke's Med Ctr, Chicago, IL, US; 7Cytheris, Inc, Paris, France; and 8Case Western Reserve Univ, Cleveland, OH, US |
| 12:15 pm 129 |
In Chronic HIV-1 infection, Cyclosporine A Provides No Sustained Immunologic Benefit to Persons Starting ART
Michael Lederman*1, L Smeaton2, K Smith3, B Rodriguez1, H Wang2, P Tebas4, S Sieg1, D Margolis5, C Pilcher5, H Valdez6, and AIDS Clinical Trials Group A5138 team
1Case Western Reserve Univ, Cleveland, OH, US; 2Statistical & Data Analysis Ctr, Harvard Univ, Boston, MA, US; 3Rush Med Coll, Chicago, IL, US; 4Univ of Pennsylvania, Philadelphia, US; 5Univ of North Carolina at Chapel Hill, US; and 6Boehringer Ingelheim |
|
